📊 QNCX Key Takeaways
Is Quince Therapeutics, Inc. (QNCX) a Good Investment?
Quince Therapeutics faces severe financial distress with negative equity of -$35.7M and a critically low current ratio of 0.53x, indicating technical insolvency. With only $5.8M in cash against annual operating burn of -$41.4M, the company has less than two months of runway before capital exhaustion. The combination of zero revenue, escalating losses (-47.8% YoY), and liabilities exceeding assets creates an untenable financial position requiring immediate restructuring or capital infusion.
Why Buy Quince Therapeutics, Inc. Stock? QNCX Key Strengths
- No long-term debt provides flexibility for potential restructuring or asset monetization
- Operates in biologics sector with potential pipeline value despite current financial distress
- Recent insider filing activity indicates core operations remain active
QNCX Stock Risks: Quince Therapeutics, Inc. Investment Risks
- Negative stockholders' equity of -$35.7M signals technical insolvency and potential shareholder wipeout
- Critical liquidity emergency: current ratio 0.53x with less than 2 months cash runway at current burn rate, requiring immediate capital raise or bankruptcy filing
- Pre-revenue model with accelerating operating losses and negative operating cash flow of -$41.4M annually, indicating unsustainable business model
Key Metrics to Watch
- Monthly cash burn rate and exact runway until capital depletion
- Emergency capital raising activities and dilution implications
- Clinical development milestones or revenue-generating partnership announcements
Quince Therapeutics, Inc. (QNCX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
QNCX Profit Margin, ROE & Profitability Analysis
QNCX vs Healthcare Sector: How Quince Therapeutics, Inc. Compares
How Quince Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Quince Therapeutics, Inc. Stock Overvalued? QNCX Valuation Analysis 2026
Based on fundamental analysis, Quince Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Quince Therapeutics, Inc. Balance Sheet: QNCX Debt, Cash & Liquidity
QNCX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Quince Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.31 indicates the company is currently unprofitable.
QNCX Revenue Growth, EPS Growth & YoY Performance
Quince Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
QNCX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Quince Therapeutics, Inc. (CIK: 0001662774)
📋 Recent SEC Filings
❓ Frequently Asked Questions about QNCX
What is the AI rating for QNCX?
Quince Therapeutics, Inc. (QNCX) has an AI rating of STRONG SELL with 97% confidence, based on fundamental analysis of SEC EDGAR filings.
What are QNCX's key strengths?
Claude: No long-term debt provides flexibility for potential restructuring or asset monetization. Operates in biologics sector with potential pipeline value despite current financial distress.
What are the risks of investing in QNCX?
Claude: Negative stockholders' equity of -$35.7M signals technical insolvency and potential shareholder wipeout. Critical liquidity emergency: current ratio 0.53x with less than 2 months cash runway at current burn rate, requiring immediate capital raise or bankruptcy filing.
What is QNCX's revenue and growth?
Quince Therapeutics, Inc. reported revenue of N/A.
Does QNCX pay dividends?
Quince Therapeutics, Inc. does not currently pay dividends.
Where can I find QNCX SEC filings?
Official SEC filings for Quince Therapeutics, Inc. (CIK: 0001662774) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is QNCX's EPS?
Quince Therapeutics, Inc. has a diluted EPS of $-1.68.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is QNCX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Quince Therapeutics, Inc. has a STRONG SELL rating with 97% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is QNCX stock overvalued or undervalued?
Valuation metrics for QNCX: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy QNCX stock in 2026?
Our dual AI analysis gives Quince Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is QNCX's free cash flow?
Quince Therapeutics, Inc.'s operating cash flow is $-41.4M, with capital expenditures of $352.0K.
How does QNCX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.53 (avg: 2).